Skip to main content


2024 SNO/ASCO CNS Metastases Conference

Leveraging Multi-Sector Collaboration to Disrupt CNS Metastases

August 8-10, 2024
  Sheraton Denver Downtown Hotel - Denver, Colorado 

Register Today!


The SNO/ASCO CNS Metastases Conference — Leveraging Multi-Sector Collaboration to Disrupt CNS Metastases — will be held August 8-10, 2024, at the Sheraton Denver Downtown Hotel in Denver, Colorado.

Jointly sponsored by the Society for Neuro-Oncology and the American Society of Clinical Oncology, the scientific content of this unique event will offer outstanding keynote and plenary addresses on a range of timely topics on the complex and rapidly evolving area of CNS metastases. Topics to be addressed include basic and translational research, as well as a broad range of clinical practice topics including radiation therapy, surgery, chemotherapy, targeted therapy/immunotherapy, multimodality therapy and clinical trials. In addition to lectures from internationally recognized experts, conference participants will have opportunities to present their work -- and to learn about advances made by others -- through short oral presentation and scientific posters selected by the scientific review committee. The theme for this year’s conference is to bring together all the key stakeholders and leverage multi-sector collaborations to disrupt barriers and streamline therapeutic advances for patients with CNS metastases.

As an adjunct to the cutting-edge multidisciplinary science that will be presented, we expect the conference in Denver will provide an outstanding and unparalleled forum for networking and socialization with like-minded colleagues from around the world who are focused on advancing CNS metastases research and patient care, as well as the opportunity to interact with exhibitors from SNO’s industry and non-profit partners.

Who Should Attend
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Data /AI Scientists, Computational scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care/Quality of Life Professionals, Industry Professionals, Drug Developers, Regulatory and Government Officials, Patient Advocates, Clinical research specialists, Clinical research organizations -- all involved in clinical trials and patient care of patients with CNS metastases.

Educational Objectives
After attending this conference, participants should be able to:
  • Explain the CNS activity of systemic agents in the context of multidisciplinary care for the treatment of CNS metastases.
  • Discuss the evolving role of novel agents with enhanced CNS penetration.
  • Discuss new developments in local therapeutic approaches and diagnostics in the treatment of CNS metastases.
  • Explain the role of the tumor microenvironment in CNS metastases.
  • Discuss innovative clinical trials designs incorporating recent advances such as liquid biopsy, novel prognostic biomarkers, and advanced neuroimaging for the treatment of CNS malignancies.
  • Outline challenges for the development and approval of novel therapies for CNS cancers.

To view the program, click here. 

Abstract Submission
The organizers of the SNO/ASCO Conference on CNS Metastases welcome the submission of original research and clinical findings addressing metastatic CNS basic science research, translational research, and clinical trials. Previously presented (encore) or not yet presented clinical trial abstracts and trials in progress are welcome but must be identified as such in the submission process. All submissions are peer-reviewed and accepted abstracts are presented as oral talks or in-person posters. Electronic posters will be available online at the start of the Conference.

CNS Metastases Abstract Submission Categories in 2024:
  • Basic Science Leptomeningeal Disease
  • Basic Science Brain Metastases
  • Spinal Cord Metastases
  • Novel Targets in CNS Metastases (non-immunologic)
  • Immuno-oncology Approaches
  • Radiation Therapy Advances
  • Surgical Advances and Device Advances
  • Multimodality Approaches
  • Neuroimaging/Radiologic Advances
  • Supportive Care, Palliative Care and QOL
  • Data Sciences/AI Advances
  • Research Methods and Trial Design Considerations
  • Ongoing Clinical Trials (poster only)
  • Translational Science
  • Biomarkers
Abstract Submission is now closed. 
Submitters of accepted abstracts will be notified in mid- to late-May.
Accepted abstracts will be published and indexed in Neuro-Oncology Advances.

Planning Committee Leadership
Priya Kumthekar, Northwestern Medicine
Hussein Tawbi, University of Texas MD Anderson Cancer Center

Co-Chairs Elect
Nancy Lin, Dana Farber Cancer Institute
Solmaz Sahebjam, Johns Hopkins University

Immediate Past Co-Chairs
Adrienne Boire, Memorial Sloan Kettering Cancer Center
Sarah Goldberg, Yale School of Medicine

Planning Committee 
Nisreen Amayiri, King Hussein Cancer Center
Stephen Bagley, University of Pennsylvania
Isabella Glitza Oliva, University of Texas MD Anderson Cancer Center 
Jona Hattangadi-Gluth, University of California, San Diego
Emilie Le Rhun, University Hospital Zurich, Switzerland
Minesh Mehta, Miami Cancer Institute
Seema Nagpal, Stanford University
Jarushka Naidoo, Johns Hopkins 
Josh Neman, University of Southern California, Los Angeles
Michael Platten, University Medical Center Mannheim
Nancy Wang, Massachusetts General Hospital
Debra Nana Yeboa, University of Texas MD Anderson Cancer Center